Affiliation:
1. Pharmacy Department, CHU Sainte-Justine, Montreal, Quebec, Canada
2. Centre de Toxicologie du Québec, Institut national de santé publique du Québec, Quebec, Quebec, Canada
3. Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada
Abstract
Introduction Occupational exposure to antineoplastic drugs can lead to long-term adverse effects on workers’ health. A reproducible Canadian surface monitoring program was established in 2010. The objective was to describe contamination with 11 antineoplastic drugs measured on 12 surfaces among hospitals participating in this annual monitoring program. Methods Each hospital sampled six standardized sites in oncology pharmacies and six in outpatient clinics. Ultra-performance liquid chromatography coupled with tandem mass spectrometry was used for cyclophosphamide, docetaxel, doxorubicin, etoposide, 5-fluorouracil, gemcitabine, irinotecan, methotrexate, paclitaxel, and vinorelbine. Platinum-based drugs were analyzed by inductively coupled plasma mass spectrometry; this excludes inorganic platinum from the environment. Hospitals filled out an online questionnaire about their practices; a Kolmogorov–Smirnov test was used for some practices. Results One hundred and twenty-four Canadian hospitals participated. Cyclophosphamide (405/1445, 28%), gemcitabine (347/1445, 24%), and platinum (71/756, 9%) were the most frequent. The 90th percentile of surface concentration was 0.01 ng/cm² for cyclophosphamide and 0.003 ng/cm² for gemcitabine. Centers that prepared 5000 or more antineoplastic per year had higher concentrations of cyclophosphamide and gemcitabine on their surfaces ( p = 0.0001). Almost half maintained a hazardous drugs committee (46/119, 39%), but this did not influence the cyclophosphamide contamination ( p = 0.051). Hazardous drugs training was more frequent for oncology pharmacy and nursing staff than for hygiene and sanitation staff. Conclusions This monitoring program allowed centers to benchmark their contamination with pragmatic contamination thresholds derived from the Canadian 90th percentiles. Regular participation and local hazardous drug committee involvement provide an opportunity to review practices, identify risk areas, and refresh training.
Subject
Pharmacology (medical),Oncology
Reference37 articles.
1. Chemical risk in hospital settings: Overview on monitoring strategies and international regulatory aspects
2. National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings 2020. Publication Number 2020-xxx (Supersedes 2016-161), https://www.cdc.gov/niosh/docket/review/docket233c/pdfs/DRAFT-NIOSH-Hazardous-Drugs-List-2020.pdf (2020, accessed 17 October 2022).
3. Defining cytotoxic drugs – you know it when you see it?
4. Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners
5. U.S. Pharmacopeial Convention. General chapter <800> hazardous drugs—handling in healthcare settings USP 39–NF 34, First Supplement. http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/usp-nf-commentary/gc__800_commentary_final.pdf (2016, accessed 10 November 2021).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献